Stocks and Investing Stocks and Investing
Fri, July 29, 2022

Sarah James Maintained (AMED) at Buy with Decreased Target to $154 on, Jul 29th, 2022


Published on 2024-10-27 22:18:03 - WOPRAI, Sarah James
  Print publication without navigation


Sarah James of Barclays, Maintained "Amedisys, Inc." (AMED) at Buy with Decreased Target from $181 to $154 on, Jul 29th, 2022.

Sarah has made no other calls on AMED in the last 4 months.



There are 9 other peers that have a rating on AMED. Out of the 9 peers that are also analyzing AMED, 3 agree with Sarah's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tao Qiu of "Stifel" Initiated at Hold and Held Target at $128 on, Wednesday, June 29th, 2022
  • Whit Mayo of "SVB Leerink" Maintained at Hold with Decreased Target to $107 on, Tuesday, June 21st, 2022
  • Scott Fidel of "Stephens & Co." Maintained at Hold with Decreased Target to $125 on, Tuesday, June 21st, 2022


These are the ratings of the 6 analyists that currently disagree with Sarah


  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $165 on, Thursday, July 28th, 2022
  • David Macdonald of "Truist Securities" Maintained at Strong Buy with Decreased Target to $150 on, Thursday, July 14th, 2022
  • Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $175 on, Tuesday, June 21st, 2022
  • Joanna Gajuk of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $102 on, Tuesday, June 21st, 2022
  • John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $180 on, Friday, April 29th, 2022
  • A.J. Rice of "Credit Suisse" Maintained at Buy with Increased Target to $182 on, Friday, April 29th, 2022
Contributing Sources